期刊
FRONTIERS IN PHARMACOLOGY
卷 7, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2016.00359
关键词
cannabidiol; epilepsy; Cbd; intoxication; refractory reriod; electrophysiological
资金
- Conselho Nacional de Desenvolvimen to Cientifico e Tecnologico (CNPq, Brazil)
- CNPq Grant (CNPq/MS/SCHE/DECIT - Pesquisas sobre Disuirbios Ncuropsiquiatricos) [26/2014, 466805/2014-4]
- Gencralitat de Cataluny /Support a les activitats del Grups de Recerca) [SGR2014/1411]
Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched extracts may have beneficial effects for children with treatment-resistant epilepsy. However, these compounds are not yet registered as medicines by regulatory agencies. We describe the cases of two children with treatment-resistant epilepsy (Case A with left frontal dysplasia and Case B with Dravet Syndrome) with initial symptom improvement after the introduction of CBD extracts followed by seizure worsening after a short time. The children presented typical signs of intoxication by Delta 9-THC (inappropriate laughter, ataxia, reduced attention, and eye redness) after using a CBD-enriched extract. The extract was replaced by the same dose of purified CBD with no Delta 9-THC in both cases, which led to improvement in intoxication signs and seizure remission. These cases support pre-clinical and preliminary clinical evidence suggesting that CBD may be effective for some patients with epilepsy. Moreover, the cases highlight the need for randomized clinical trials using high-quality and reliable substances to ascertain the safety and efficacy of cannabinoids as medicines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据